On January 12, 2018, Khiron Life Sciences Corp. closed the transaction. The company issued 11,230,000 subscription receipts for gross proceeds of CAD 11,230,000. The transaction included participation from 196 placees , which included 21 from professionals’ group for 611,000 shares and insider Darren Collins, Chief Financial Officer of the company, for 21,000 shares. The company received acceptance for the filing documentation from TSX Venture Exchange. Each subscription receipt was exchanged for common shares and common share purchase warrants of the resulting issuer on a 1 for 1 basis. All securities issued on a post-consolidation basis.